These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15608561)

  • 1. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.
    Foucher C; Rattier S; Flavell DM; Talmud PJ; Humphries SE; Kastelein JJ; Ayyobi A; Pimstone S; Frohlich J; Ansquer JC; Steiner G;
    Pharmacogenetics; 2004 Dec; 14(12):823-9. PubMed ID: 15608561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
    Brisson D; Ledoux K; Bossé Y; St-Pierre J; Julien P; Perron P; Hudson TJ; Vohl MC; Gaudet D
    Pharmacogenetics; 2002 Jun; 12(4):313-20. PubMed ID: 12042669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.
    Irvin MR; Zhang Q; Kabagambe EK; Perry RT; Straka RJ; Tiwari HK; Borecki IB; Shimmin LC; Stuart C; Zhong Y; Hixson JE; Arnett DK
    Pharmacogenet Genomics; 2012 May; 22(5):367-72. PubMed ID: 22336959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
    Lai CQ; Arnett DK; Corella D; Straka RJ; Tsai MY; Peacock JM; Adiconis X; Parnell LD; Hixson JE; Province MA; Ordovas JM
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1417-25. PubMed ID: 17431185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls.
    Gouni-Berthold I; Giannakidou E; Faust M; Berthold HK; Krone W
    Atherosclerosis; 2005 Dec; 183(2):336-41. PubMed ID: 16285997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate and metabolic syndrome.
    Kraja AT; Province MA; Straka RJ; Ordovas JM; Borecki IB; Arnett DK
    Endocr Metab Immune Disord Drug Targets; 2010 Jun; 10(2):138-48. PubMed ID: 20406163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
    Lemieux I; Salomon H; Després JP
    Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Morieri ML; Shah HS; Sjaarda J; Lenzini PA; Campbell H; Motsinger-Reif AA; Gao H; Lovato L; Prudente S; Pandolfi A; Pezzolesi MG; Sigal RJ; Paré G; Marcovina SM; Rotroff DM; Patorno E; Mercuri L; Trischitta V; Chew EY; Kraft P; Buse JB; Wagner MJ; Cresci S; Gerstein HC; Ginsberg HN; Mychaleckyj JC; Doria A
    Diabetes; 2020 Apr; 69(4):771-783. PubMed ID: 31974142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate.
    Brouillette C; Bossé Y; Pérusse L; Gaudet D; Vohl MC
    J Hum Genet; 2004; 49(8):424-432. PubMed ID: 15249972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control.
    Cavallero E; Dachet C; Assadolahi F; Martin C; Navarro N; Ansquer JC; Corda C; Foucher C; Juhan-Vague I; Jacotot B
    Atherosclerosis; 2003 Jan; 166(1):151-61. PubMed ID: 12482562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.
    Guérin M; Bruckert E; Dolphin PJ; Turpin G; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):763-72. PubMed ID: 8640404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians.
    Shin MJ; Kanaya AM; Krauss RM
    Atherosclerosis; 2008 Jun; 198(2):313-9. PubMed ID: 18061194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
    Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
    Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor alpha, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study.
    Do HQ; Nazih H; Luc G; Arveiler D; Ferrières J; Evans A; Amouyel P; Cambien F; Ducimetière P; Bard JM
    Metabolism; 2009 Mar; 58(3):283-9. PubMed ID: 19217440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
    Kasai S; Inoue T; Yoshitomi H; Hihara T; Matsuura F; Harada H; Shinoda M; Tanaka I
    J Pharmacol Sci; 2008 Sep; 108(1):40-8. PubMed ID: 18776709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.
    Tan CE; Chew LS; Tai ES; Chio LF; Lim HS; Loh LM; Shepherd J
    Atherosclerosis; 2001 Feb; 154(2):469-74. PubMed ID: 11166781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
    Gao F; Ballantyne C; Ma L; Virani SS; Keinan A; Brautbar A
    Atherosclerosis; 2014 Jun; 234(2):249-53. PubMed ID: 24704626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
    Insua A; Massari F; Rodríguez Moncalvo JJ; Rubén Zanchetta J; Insua AM
    Endocr Pract; 2002; 8(2):96-101. PubMed ID: 11942772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.